Abstract

In this work, we have reported the design, synthesis, in vitro, and in silico enzymatic evaluation of new bis-4-hydroxycoumarin-based phenoxy-1,2,3-triazole-N-phenylacetamide derivatives 5a-m as potent α-glucosidase inhibitors. All the synthesized analogues showed high inhibition effects against α-glucosidase (IC50 values ranging between 6.0 ± 0.2 and 85.4 ± 2.3 µM) as compared to the positive control acarbose (IC50 = 750.0 ± 0.6 µM). Among the newly synthesized compounds 5a-m, 2,4-dichloro-N-phenylacetamide derivative 5i with inhibition effect around 125-folds more than the acarbose was identified as the most potent entry. A structure–activity relationship (SAR) study about the title compounds 5a-m demonstrated that the inhibition effects of these compounds depend on the pattern of substitution on the N-phenylacetamide ring. The interaction modes and binding energies in the active site of enzyme of the important analogues (in term of SAR study) were evaluated through molecular docking study. Molecular dynamics and prediction of pharmacokinetic properties and toxicity of the most potent compound 5i also evaluated and the obtained data was compared with the acarbose.

Details

Title
Design of new α-glucosidase inhibitors based on the bis-4-hydroxycoumarin skeleton: Synthesis, evaluation, and in silico studies
Author
Soleimani, Zahra 1 ; Mohammadi, Mohammad 2 ; Halimi, Mohammad 3 ; Safapoor, Sajedeh 1 ; Dastyafteh, Navid 1 ; Safaie, Elham 1 ; Mojtabavi, Somayeh 4 ; Faramarzi, Mohammad Ali 4 ; Bozorgi-Koushalshahi, Maryam 1 ; Larijani, Bagher 1 ; Mohammadi-Khanaposhtani, Maryam 5 ; Mahdavi, Mohammad 1 

 Tehran University of Medical Sciences, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Tehran University of Medical Sciences, Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Islamic Azad University, Department of Biology, Babol Branch, Babol, Iran (GRID:grid.467532.1) (ISNI:0000 0004 4912 2930) 
 Tehran University of Medical Sciences, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Babol University of Medical Sciences, Cellular and Molecular Biology Research Center, Health Research Institute, Babol, Iran (GRID:grid.411495.c) (ISNI:0000 0004 0421 4102) 
Pages
18693
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3092133955
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.